Denka Deepens the Strategic Partnership with PlexBio Through Acquiring Over One-third of Its Stake 

PlexBio Co.,Ltd., a Taipei, Taiwan-based clinical cancer diagnostics developer, and Denka Co., Ltd., Japanese chemical products firm has been in close collaboration since the signing of memorandum of understanding in 2015.

On September 19th, PlexBio announced that Denka acquired one-third of its stake. Denka thus becomes the biggest shareholder of PlexBio. This transaction is the largest investment between Taiwan and Japan in the biomedical industry. The two companies held a ceremony in celebration of the deepened strategic partnership and plans to expand product portfolio, enter various diagnostics markets, and further extend into new areas. Many distinguished guests attended the ceremony, including Mei-yueh Ho, the national policy to the president, Dr. Johnsee Lee, Chairman of Taiwan Biotech Industry Organization, Dr. Annie Liu, Director of the Office of Science and Technology of the Executive Yuan, Shu-Long Wang, Deputy Director of Consumer Goods and Chemical Industries Division of the Industrial Development Bureau, and other experts in the industry.

Dr. Dean Tsao, CEO and chairman of PlexBio, mentioned that the reason he founded PlexBio was because there was a chance in entering the IVD market of Taiwan back in 2009, which was not fully developed, and that he wanted to contribute his successful overseas experience to his home country, Taiwan. PlexBio thereby became the fourth company he established. In 2010, Dr. Dean Tsao founded its R&D laboratory, and started training local talents. In 2013, he set up a factory as well as a marketing base in Jiangsu Province, China.

PlexBio’s commitment to cancer discovery and treatment begins with early detection and the identification of precision treatments. It’s proprietary cutting-edge multiplexing platform leverages patented Precision Image Code (πCode™) MicroDisc technology to provide rapid, cost-effective, streamline cancer diagnostics. Companion diagnostics, early detection, screening tests of diseases, prenatal diagnosis are its applications. The total automation system IntelliPlex™ platform, is applicable to a various fields of biomedical research, and offers huge market opportunities.

Hideki Takahashi, Executive Officer of Life Innovation of Denka believes that πCode™ MicroDiscs and the IntelliPlex™ platform has a potential to resolve the problem of diseases that still pose threat to human.

The partnership between PlexBio and Denka will be expected to achieve three overall goals:

1. Build a Taiwan-based ecosystem to support IVD products.
2. Develop multiplex applications.
3. Expand business into European Union, Japan and the emerging markets in Asia.

About Denka

Established in 1915, the Tokyo-based Denka manufactures and supplies chemical products globally across a wide range of fields, including bacteriology, virology, clinical chemistry, and immunochemistry. The company is listed on the Tokyo Stock Exchange (stock code:4061).

About PlexBio

Established in 2010, the Taipei, Taiwan-based PlexBio designs, develops and manufactures IVD products and instrumentations. Precision Image Code (πCode™) MicroDisc technology and IntelliPlex™ platform are two independent novel technologies developed by PlexBio and can be widely used in various clinical IVD diagnostics. The company is a listed company at Taiwan emerging stock market.

Author

GeneOnline

Related Post

Ranking & Reports

9 Leading Molecular Diagnostics Companies to Watch in Taiwan

2021-11-15

Asia-Pacific

Weekly in Asia | SEP-2

2019-09-24

Asia-Pacific

BIO Asia-Taiwan 2019 – Biotech as the Next Growth Engine for Asia

2019-07-26